Experimental drug targets Cancer's internal brakes in patients out of options
NCT ID NCT02264613
Summary
This early-stage trial tested a new drug called ALRN-6924, alone or with another cancer drug, in 142 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in patients whose cancers have a specific genetic feature called wild-type p53. The study was completed to gather initial safety and effectiveness data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Birmingham, Alabama, 35294, United States
-
Study site
Duarte, California, 91010, United States
-
Study site
Denver, Colorado, 80218, United States
-
Study site
Sarasota, Florida, 34232, United States
-
Study site
Tampa, Florida, 33612, United States
-
Study site
Boston, Massachusetts, 02114, United States
-
Study site
Boston, Massachusetts, 02215, United States
-
Study site
New York, New York, 10065, United States
-
Study site
The Bronx, New York, 10461, United States
-
Study site
Greenville, South Carolina, 29605, United States
-
Study site
Nashville, Tennessee, 37203, United States
-
Study site
Houston, Texas, 77030, United States
-
Study site
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.